Atlas Trials

Monotherapy With Eribulin In Her2 Negative Metastatic Breast Cancer as a First Line Treatment

Clinical trial NCT02061085 · COMPLETED

Trial details

NCT number
NCT02061085
Sponsor
MedSIR
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Breast NeoplasmMetastasis
Start date
2013-07-01
Primary completion
2015-12-01
Enrollment
53

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.